Increased plasma sestrin2 concentrations in patients with chronic heart failure and predicted the occurrence of major adverse cardiac events: A 36-month follow-up cohort study

2019 ◽  
Vol 495 ◽  
pp. 338-344 ◽  
Author(s):  
Haixiong Wang ◽  
Na Li ◽  
Xin Shao ◽  
Jun Li ◽  
Liping Guo ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cohort Study ◽  
Chronic Heart Failure ◽  
Major Adverse Cardiac Events ◽  
Cardiac Events ◽  
Adverse Cardiac Events

scholarly journals Plasma IL-37 Elevated in Patients with Chronic Heart Failure and Predicted Major Adverse Cardiac Events: A 1-Year Follow-Up Study

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Xiling Shou ◽  
Jing Lin ◽  
Cui Xie ◽  
Yi Wang ◽  
Chaofeng Sun
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Cox Regression ◽  
Left Ventricular ◽  
Major Adverse Cardiac Events ◽  
Left Ventricular Ejection ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cardiac Events ◽  
Cox Regression Analysis ◽  
Adverse Cardiac Events

A great number of basic and clinical studies have demonstrated that inflammatory cytokines play an important role in the development and progression of chronic heart failure (CHF). However, there is limited information about the role of novel cytokine interleukin-37 (IL-37) in heart failure. We measured plasma IL-37 levels by enzyme-linked immunosorbent assay (ELISA) in 158 patients with chronic heart failure and 30 control subjects. Our results showed that plasma IL-37 levels were significantly elevated in patients with CHF compared with healthy controls (143.73 ± 26.83 pg/ml versus 45.2 ± 11.56 pg/ml,P<0.001). Furthermore, plasma IL-37 levels were positively correlated with hs-CRP, hs-TnT, and NT-proBNP and negatively correlated with left ventricular ejection function (LVEF). 11 patients died of cardiovascular cause, and 27 HF patients were rehospitalized for worsening HF within 12 months. Multivariate Cox regression analysis showed that plasma IL-37 is an independent predictor of major adverse cardiac events (MACE). Furthermore, CHF patients with >99 pg/ml plasma IL-37 had significantly higher incidences of MACE within 12 months. Our data suggest that plasma IL-37 may play a role in the pathogenesis of CHF and may be a novel predictor of poor prognosis in HF patients.

Longitudinally Measured Fibrinolysis Factors are Strong Predictors of Clinical Outcome in Patients with Chronic Heart Failure: The Bio-SHiFT Study

2019 ◽  
Vol 119 (12) ◽  
pp. 1947-1955
Author(s):  
Victor J. van den Berg ◽  
Elke Bouwens ◽  
Victor A. W. M. Umans ◽  
Moniek de Maat ◽  
Olivier C. Manintveld ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Plasminogen Activator ◽  
Left Ventricular ◽  
Tissue Type ◽  
Cardiac Events ◽  
Type Plasminogen Activator ◽  
Adverse Cardiac Events ◽  
Pai 1

Abstract Objective This article investigates whether longitudinally measured fibrinolysis factors are associated with cardiac events in patients with chronic heart failure (CHF). Methods A median of 9 (interquartile range [IQR] 5–10) serial, tri-monthly blood samples per patient were prospectively collected in 263 CHF patients during a median follow-up of 2.2 (IQR 1.4–2.5) years. Seventy patients (cases) reached the composite endpoint of cardiac death, heart failure hospitalization, left ventricular assist device, or heart transplantation. From all longitudinal samples, we selected baseline samples in all patients and the last two samples before the event in cases or the last sample available in event-free patients. Herein, we measured plasminogen activator inhibitor 1 (PAI-1), tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), and soluble urokinase plasminogen activator surface receptor (suPAR). Associations between temporal biomarker patterns during follow-up and the cardiac event were investigated using a joint model. Results Cases were on average older and showed higher New York Heart Association class than those who remained event-free. They also had lower blood pressures, and were more likely to have diabetes, renal failure, and atrial fibrillation. Longitudinally measured PAI-1, uPA, and suPAR were independently associated with adverse cardiac events after correction for clinical characteristics (hazard ratio [95% confidence interval]) per standard deviation increase of 2.09 (1.28–3.45) for PAI-1, 1.91 (1.18–3.24) for uPA, and 3.96 (2.48–6.63) for suPAR. Serial measurements of tPA were not significantly associated with the event after correction for multiple testing. Conclusion Longitudinally measured PAI-1, uPA, and suPAR are strongly associated with adverse cardiac events during the course of CHF. If future research confirms our results, these fibrinolytic factors may carry potential for improved, and personalized, heart failure surveillance and treatment monitoring.

scholarly journals Serum Chemerin as a Novel Prognostic Indicator in Chronic Heart Failure

2019 ◽  
Vol 8 (15) ◽  
Author(s):  
Xiang Zhou ◽  
Yifei Tao ◽  
Yuqi Chen ◽  
Weiting Xu ◽  
Zhiyuan Qian ◽  
...  
Keyword(s):  
Heart Failure ◽  
Regression Analysis ◽  
Chronic Heart Failure ◽  
Cox Regression ◽  
Prognostic Indicator ◽  
Hazard Ratio ◽  
Major Adverse Cardiac Events ◽  
Cardiac Events ◽  
Cox Regression Analysis ◽  
Adverse Cardiac Events

Background It has been documented that circulating chemerin is associated with inflammation, metabolic syndrome, and coronary artery disease. The present study was aimed to evaluate the prognostic value of serum chemerin in patients with chronic heart failure. Methods and Results We included 834 patients with chronic heart failure in a prospective cohort study and investigated the association between serum chemerin and clinical outcomes using multivariate Cox regression analysis. Patients with higher chemerin levels tended to be older and women and were more likely to experience hypertension, diabetes mellitus, and hyperlipemia. Cox regression analysis showed that chemerin was a significant predictor of major adverse cardiac events (hazard ratio, 1.83; 95% CI, 1.31–2.96) after adjustment for conventional risk factors. Net reclassification and integrated discrimination improvements for major adverse cardiac events were markedly improved by addition of chemerin to the reference model. In addition, chemerin was an independent predictor of all‐cause mortality (hazard ratio, 1.67; 95% CI, 1.21–2.73) after multivariable adjustment. Furthermore, the Kaplan–Meier survival analysis revealed that chemerin was a prognostic indicator of major adverse cardiac events in patients with chronic heart failure and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels above and below the median. Conclusions Our study suggests that chemerin is a novel serum marker for predicting major adverse cardiac events in patients with chronic heart failure.

scholarly journals Post PCI with stenting Follow-Up in Women for 7 Years in Public Sector Tertiary Care Cardiac Unit. Retrospective Study

2020 ◽  
Vol 5 (2) ◽  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Menopausal Status ◽  
Major Adverse Cardiac Events ◽  
Hormonal Contraceptives ◽  
Cardiac Events ◽  
Adverse Cardiac Events ◽  
Long Term Follow Up

Introduction: Despite of the fact that there is continual improvement in diagnostic and therapeutic procedures in catherization Lab introduction of better catheter techniques and new-generation stents and with the acquisition of knowledge from largescale clinical trials Still women appear to have a higher in-hospital mortality after PCI with stenting and during long term follow up specially in developing countries of South Asia the, Reason could be multi-factorial in women. The objectives: The goals of treatment in PCI with stenting in Women is to improve quality of life, to prevent CHD from becoming symptomatic, prevent myocardial infarction, cardiac death and heart failure, the approaches to achieve these goals at the societal or individual level in this regards differ among various countries, the data that have been published are often limited due to the relatively small number of western women. It is important to collect data in under developed countries on outcomes of long term follow up of women with AMI after PCI with stenting to change the global perception of treatment of women with myocardial infarction. Material and Method: Out of 3300 patients, underwent successful PCI with stenting during 2010 to 2016 in Cath Lab of cardiology department of Dow University of Health and Sciences Karachi Pakistan , 577 patients with Sciences Karachi Pakistan, 577 patients with Myocardial infarction within 7 days were included in study and they constitute the present followup population. Additional data regarding noncardiac comorbid diseases and Risk factors were obtained along with crucial aspects of women’s health, such as menopausal status, use of hormonal contraceptives, Follow-up was planned after 1 month and then with annualy for 7 years. The primary end point of study were the long-term rate of major adverse cardiac events (i.e. death, Infarction, and repeat revascularization). The secondary end points were the individual components of the major adverse cardiac events and stent thrombosis. Result: This observational study was conducted by reviewing the record of cases performed and getting information on follow up visits of patients for 7 years from June 2010 to June 2016, out of total 3300 procedure 577 patients were included in the study who underwent PCI with stenting with in the 7 day of Myocardial infarction consisting of 346 patient from urban and 237 people from Rural areas of Sindh Balochistan Provinice of Pakistan Revascularization with stenting was performed in 313 patients 40-50 years of age followed by 219 patients 56-70 years of age in comparison to 23 in older group > 70 years and 22 in younger age < 40 years ,In 528 (91.5%)patients PCI with BMS, in 28 (4.8%)patients DES alone and in 21 (3.6%)patients with BMS and DES performed The odds of short-term mortality were significantly higher among older post - menopausal group compared to premenopausal patients <55. I3 patients (5 patients during hospitalization) and 8 patients died within 30 days after PCI. Total 57((9.8%) patient died during7 years follow up, 31 (58.5%) cases due to comorbid conditions, and remaining 27 patients death was due to myocardial infarction in 13 (39.4%). Arrhythmias in 5 (9.4%) and worsening of heart Failure in 8 (42.1%) elderly patients. Patient had complete Closure of Target Vessel, 28 (4.8%) had Re PCI on 7 years follow up and CABG was performed in 13 (2.2%). Patients main reason could be noncompliance of therapy in 71 (12.3%) in patients.

scholarly journals Major Adverse Cardiac Events and Mortality Associated with Electroconvulsive Therapy

2019 ◽  
Vol 130 (1) ◽  
pp. 83-91 ◽  
Author(s):  
Andreas Duma ◽  
Mathias Maleczek ◽  
Basil Panjikaran ◽  
Harald Herkner ◽  
Theodore Karrison ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Edema ◽  
Acute Heart Failure ◽  
Electroconvulsive Therapy ◽  
Meta Analysis ◽  
Incidence Rates ◽  
Major Adverse Cardiac Events ◽  
Cardiac Events ◽  
Total N ◽  
Adverse Cardiac Events

Abstract EDITOR’S PERSPECTIVE What We Already Know about This Topic The incidence of major adverse cardiac events after electroconvulsive therapy is not known What This Article Tells Us That Is New Major adverse cardiac events and death after electroconvulsive therapy are infrequent and occur in about 1 of 50 patients and after about 1 of 200 to 500 electroconvulsive therapy treatments Background Cardiac events after electroconvulsive therapy have been reported sporadically, but a systematic assessment of the risk is missing. The goal of this study was to obtain a robust estimate of the incidence of major adverse cardiac events in adult patients undergoing electroconvulsive therapy. Methods Systematic review and meta-analysis of studies that investigated electroconvulsive therapy and reported major adverse cardiac events and/or mortality. Endpoints were incidence rates of major adverse cardiac events, including myocardial infarction, arrhythmia, pulmonary edema, pulmonary embolism, acute heart failure, and cardiac arrest. Additional endpoints were all-cause and cardiac mortality. The pooled estimated incidence rates and 95% CIs of individual major adverse cardiac events and mortality per 1,000 patients and per 1,000 electroconvulsive therapy treatments were calculated. Results After screening of 2,641 publications and full-text assessment of 284 studies, the data of 82 studies were extracted (total n = 106,569 patients; n = 786,995 electroconvulsive therapy treatments). The most commonly reported major adverse cardiac events were acute heart failure, arrhythmia, and acute pulmonary edema with an incidence (95% CI) of 24 (12.48 to 46.13), 25.83 (14.83 to 45.00), and 4.92 (0.85 to 28.60) per 1,000 patients or 2.44 (1.27 to 4.69), 4.66 (2.15 to 10.09), and 1.50 (0.71 to 3.14) per 1,000 electroconvulsive therapy treatments. All-cause mortality was 0.42 (0.11 to 1.52) deaths per 1,000 patients and 0.06 (0.02 to 0.23) deaths per 1,000 electroconvulsive therapy treatments. Cardiac death accounted for 29% (23 of 79) of deaths. Conclusions Major adverse cardiac events and death after electroconvulsive therapy are infrequent and occur in about 1 of 50 patients and after about 1 of 200 to 500 electroconvulsive therapy treatments.

scholarly journals Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin

2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Celestino Sardu ◽  
Nunzia D’Onofrio ◽  
Michele Torella ◽  
Michele Portoghese ◽  
Francesco Loreni ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Adipose Tissue ◽  
Artery Bypass ◽  
Major Adverse Cardiac Events ◽  
Cardiac Events ◽  
Metformin Therapy ◽  
Adverse Cardiac Events ◽  
Factor Α

Abstract Background/objectives Pericoronary adipose tissue inflammation might lead to the development and destabilization of coronary plaques in prediabetic patients. Here, we evaluated inflammation and leptin to adiponectin ratio in pericoronary fat from patients subjected to coronary artery bypass grafting (CABG) for acute myocardial infarction (AMI). Furthermore, we compared the 12-month prognosis of prediabetic patients compared to normoglycemic patients (NG). Finally, the effect of metformin therapy on pericoronary fat inflammation and 12-months prognosis in AMI-prediabetic patients was also evaluated. Methods An observational prospective study was conducted on patients with first AMI referred for CABG. Participants were divided in prediabetic and NG-patients. Prediabetic patients were divided in two groups; never-metformin-users and current-metformin-users receiving metformin therapy for almost 6 months before CABG. During the by-pass procedure on epicardial coronary portion, the pericoronary fat was removed from the surrounding stenosis area. The primary endpoints were the assessments of Major-Adverse-Cardiac-Events (MACE) at 12-month follow-up. Moreover, inflammatory tone was evaluated by measuring pericoronary fat levels of tumor necrosis factor-α (TNF-α), sirtuin 6 (SIRT6), and leptin to adiponectin ratio. Finally, inflammatory tone was correlated to the MACE during the 12-months follow-up. Results The MACE was 9.1% in all prediabetic patients and 3% in NG-patients. In prediabetic patients, current-metformin-users presented a significantly lower rate of MACE compared to prediabetic patients never-metformin-users. In addition, prediabetic patients showed higher inflammatory tone and leptin to adiponectin ratio in pericoronary fat compared to NG-patients (P < 0.001). Prediabetic never-metformin-users showed higher inflammatory tone and leptin to adiponectin ratio in pericoronary fat compared to current-metformin-users (P < 0.001). Remarkably, inflammatory tone and leptin to adiponectin ratio was significantly related to the MACE during the 12-months follow-up. Conclusion Prediabetes increase inflammatory burden in pericoronary adipose tissue. Metformin by reducing inflammatory tone and leptin to adiponectin ratio in pericoronary fat may improve prognosis in prediabetic patients with AMI. Trial registration Clinical Trial NCT03360981, Retrospectively Registered 7 January 2018

Predicting mortality for patients with heart failure beyond oxygen consumption: a prognostic risk score

2021 ◽  
Author(s):  
Hanaa Shafiek ◽  
Andres Grau ◽  
Jaume Pons ◽  
Pere Pericas ◽  
Xavier Rossello ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Risk Score ◽  
Cardiac Transplantation ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Functional Evaluation ◽  
Cardiac Events ◽  
Ventricular Ejection Fraction

Background: Cardiopulmonary exercise test (CPET) is a crucial tool for the functional evaluation of cardiac patients. We hypothesized that VO2 max and VE/VCO2 slope are not the only parameters of CPET able to predict major cardiac events (mortality or cardiac transplantation urgently or elective). Objectives: We aimed to identify the best CPET predictors of major cardiac events in patients with severe chronic heart failure and to propose an integrated score that could be applied for their prognostic evaluation. Methods: We evaluated 140 patients with chronic heart failure who underwent CPET between 2011 and 2019. Major cardiac events were evaluated during follow-up. Univariate and multivariate logistic regression analysis were applied to study the predictive value of different clinical, echocardiographic and CPET parameters in relation to the major cardiac events. A score was generated and c-statistic was used for the comparisons. Results: Thirty-nine patients (27.9%) died or underwent cardiac transplantation over a median follow-up of 48 months. Five parameters (maximal workload, breathing reserve, left ventricular ejection fraction, diastolic dysfunction and non-idiopathic cardiomyopathy) were used to generate a risk score that had better risk discrimination than NYHA dyspnea scale, VO2 max, VE/VCO2 slope > 35 alone, and combined VO2 max and VE/VCO2 slope (p= 0.009, 0.004, < 0.001 and 0.005 respectively) in predicting major cardiac events. Conclusions: A composite score of CPET and clinical/echocardiographic data is more reliable than the single use of VO2max or combined with VE/VCO2 slope to predict major cardiac events.

Sign in / Sign up

Export Citation Format

Share Document